

## FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users

August 2015

### ATTORNEYS

Landmon, Chad

Ropka, PhD, Stacie

### PRACTICE AREAS

FDA

Intellectual Property

Stacie Ropka, PhD and Chad Landmon

*GxP Lifeline*

Axinn Counsel Stacie Ropka and Partner Chad Landmon authored, "FDA Regulation of CT/Ps – Impact of New Guidances on Manufacturers and Users," which was published in MasterControl's GxP Lifeline newsletter.

[Click here to read the article.](#)